Vitrakvi Approved
New Drug Approved for Patients with Rare Gene Fusion By Sara Rothschild, MPH, Vice President, Program Services & Jerry Call, Data Analyst The Food and Drug Administration granted accelerated approval on November 26th to [...]
Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
Generic Imatinib Update
On February 1, 2016, there was a commercial launch of the generic version of imatinib mesylate (Gleevec) which is approved for CML patients by the FDA. As the first to file for generic marketing [...]
Webcast Provides Perspective on Generic Imatinib
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time [...]
Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]
Proton Pump Inhibitors Linked to Kidney Disease
A recent study published in the JAMA Internal Medicine reports a link between the use of proton pump inhibitors (PPIs) and an increased risk of kidney disease. More research is warranted to show PPIs [...]
Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?
Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. On February 1, 2016, [...]
Adjuvant Imatinib Study Updates Results
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
Immunotherapy: Game Changing Cancer Treatments
Two recent articles summarize the promise that immunotherapy provides for the future of cancer treatment. Immunotherapy refers to treatments that aid your own immune system in fighting cancer cells. The first, from U.S. News [...]
Need for Extended Adjuvant Treatment to Prevent Recurrence in GIST May Be Underestimated
A recent study in JAMA Oncology found that patients who undergo primary GIST resection might not receive the optimal recommended duration of adjuvant therapy, which can impact their recurrence-free survival (RFS).The study was conducted by [...]
